Back

Nektar wins $90 million jury award against Eli Lilly

Verifying
  • Nektar Therapeutics won a jury award against Eli Lilly over a rezpegaldesleukin licensing agreement.
  • $90 million was awarded, with interest and final judgment still pending.
  • Nektar began two global Phase 3 ZENITH AD trials in July 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.